Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

New Exo-PDAC Assay Discovered for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC)

Biological Dynamics, Inc discovered new Exo-PDAC, liquid biopsy assay for the early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk adults.

Globally, pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal forms of cancer.

Exo-PDAC is the first assay using novel alternating current electrokinetic-based technology for early disease detection such as cancer, Alzheimer’s disease, and infectious diseases.

Exo-PDAC requires a small amount of blood from patients to analyse minimal sample preparation or processing.

By 2040, PDAC is expected to be the second common cancer leading to deaths due to the fact that the disease is asymptomatic in its initial stages. Patients undergo diagnosis during advanced stages of disease progression when treatments are limited. Detection of PDAC biomarkers at an early stage would help patients in further disease progression or metastasizes. However, this requires high degree of sensitivity and specificity where conventional laboratory testing methods lack. Early pancreatic cancer detection may save life of many individuals.  

U.S. Food and Drug Administration (FDA) grants breakthrough device designation for Exo-PDAC, early-stage pancreatic cancer detection test.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024